Limits...
Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine for the prevention of genital warts in males: profile report. demail@springer.com.

Garnock-Jones KP, Giuliano AR - Drugs R D (2012)

Bottom Line: †Adapted and reproduced from the original article published in Drugs 2011; 71 (5): 591-602.[1].

View Article: PubMed Central - PubMed

Affiliation: Adis, Auckland, New Zealand.

ABSTRACT
†Adapted and reproduced from the original article published in Drugs 2011; 71 (5): 591-602.[1].

Show MeSH

Related in: MedlinePlus

Features and properties of the quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine (Gardasil®)[1]
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585902&req=5

Tab1: Features and properties of the quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine (Gardasil®)[1]

Mentions: The quadrivalent HPV types 6, 11, 16, 18 vaccine (Gardasil®; hereafter referred to as the quadrivalent HPV vaccine) is a noninfectious recombinant vaccine and comprises purified virus-like particles derived from the L1 capsid proteins of HPV types 6, 11, 16, and 18.[11] Each dose contains approximately 20, 40, 40, and 20 µg of each virus-like particle type, respectively, and includes 225 µg of amorphous aluminium hydroxyphosphate sulfate adjuvant (AAHS).[11] It was approved in females in the US in 2006[12] for the prevention of various diseases caused by HPV types 6, 11, 16, and 18, and has recently been approved in males for the prevention of genital warts caused by HPV types 6 and 11.[11] Over 61 million doses of the quadrivalent HPV vaccine have been distributed worldwide.[13] The features and properties of the quadrivalent HPV vaccine are presented in table I.[1]Table I


Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine for the prevention of genital warts in males: profile report. demail@springer.com.

Garnock-Jones KP, Giuliano AR - Drugs R D (2012)

Features and properties of the quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine (Gardasil®)[1]
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585902&req=5

Tab1: Features and properties of the quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine (Gardasil®)[1]
Mentions: The quadrivalent HPV types 6, 11, 16, 18 vaccine (Gardasil®; hereafter referred to as the quadrivalent HPV vaccine) is a noninfectious recombinant vaccine and comprises purified virus-like particles derived from the L1 capsid proteins of HPV types 6, 11, 16, and 18.[11] Each dose contains approximately 20, 40, 40, and 20 µg of each virus-like particle type, respectively, and includes 225 µg of amorphous aluminium hydroxyphosphate sulfate adjuvant (AAHS).[11] It was approved in females in the US in 2006[12] for the prevention of various diseases caused by HPV types 6, 11, 16, and 18, and has recently been approved in males for the prevention of genital warts caused by HPV types 6 and 11.[11] Over 61 million doses of the quadrivalent HPV vaccine have been distributed worldwide.[13] The features and properties of the quadrivalent HPV vaccine are presented in table I.[1]Table I

Bottom Line: †Adapted and reproduced from the original article published in Drugs 2011; 71 (5): 591-602.[1].

View Article: PubMed Central - PubMed

Affiliation: Adis, Auckland, New Zealand.

ABSTRACT
†Adapted and reproduced from the original article published in Drugs 2011; 71 (5): 591-602.[1].

Show MeSH
Related in: MedlinePlus